Table 1.
Summary of literature related to first-line chemotherapy for metastatic bladder cancer.
| Sternberg et al. [7] | Sternberg et al. [7] | Von der Masse et al. [8] | Von der Masse et al. [8] | Ecke et al. [9] | Bellmunt et al. [10] | Bellmunt et al. [10] | Dogliotti et al. [11] | Dogliotti et al. [11] | Dreicer et al. [12] | Dreicer et al. [12] | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemotherapy regime | MVAC | HD-MVAC + GCSF | MVAC | GC | GC + Pac | MVAC | M-CAVI | GC | Gem-Carbo | MVAC | Carbo-Pac |
| Response Rate (%) | 58 | 72 | 45.7 | 49.4 | 64.7 | 52 | 39 | 49.1 | 40 | 35.9 | 28.2 |
| Complete Response rate (%) | 11 | 25 | 11.9 | 12.2 | 29.4 | 12.5 | 0 | 14.5 | 1.8 | 12.8 | 2.6 |
| Median time to progressive disease (months) | 9.6 | 11.1 | 7.4 | 7.4 | 7 | 8.3 | 7.7 | 8.7 | 5.2 | ||
| Median survival (months) | 14.1 | 15.5 | 14.8 | 13.8 | 18.5 | 16 | 9 | 12.8 | 9.8 | 15.4 | 13.8 |
| Toxicity | |||||||||||
| Grade 3 or 4 Neutropenia (%) |
62 | 20 | 82 | 71 | 41.2 | 34.6 | 45.4 | 77 | 29 | ||
| Neutropenic sepsis or febrile neutropenia (%) | 26 | 10 | 12 | 1 | 32.4 | 18 | 3.2 | ||||
| Drug-related deaths (%) |
4 | 3 | 3 | 1 | 4 | 0 | 2.3 | 2.4 |